Seagen Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Seagen Inc (SGEN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Seagen Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2,300M vs 206,034M combined for tracked competitors (1.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+12.8% annualized vs trailing 12 months), vs decelerating (-43.7%) for its tracked peer group.
- Growth: Seagen Inc generated 27.1% revenue growth year over year in Q3 2023, vs -1.2% for its tracked competitors combined.
- Profitability: Its -33.3% net margin compares with 15.2% for the peer group.
- Peer revenue share: Seagen Inc accounted for 2.2% of combined revenue among its tracked peer group, up from 1.7% a year earlier.
- Peer differentiation: Revenue per employee of $1.92M compares with $1.22M for the peer group (1.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SGEN Sales vs. its Competitors, Q3 2023
Seagen Inc reported revenue growth of 27.11 % year on year in Q3 2023, above its competitors' combined revenue change of -1.24 %.
With a net margin of -33.27 %, Seagen Inc reported lower profitability than its competitors (15.22 %).
Seagen Inc generated 2.19 % of the combined sales of its peer group, up from 1.71 % a year earlier.
Seagen Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Seagen Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Seagen Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (12) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Seagen Inc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.7% year over year, combined, vs 27.1% for Seagen Inc. Seagen Inc's share of combined industry revenue moved from 1.40% to 1.48%, a gain of 0.07 percentage points.
Seagen Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Seagen Inc | No | Yes | Yes | No |
| Competitors combined (80) | ||||
| High-Confidence Competitors (14) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SGEN Stock Performance relative to its Competitors
SGEN Stock Performance relative to High-Confidence Competitors
SGEN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 2 | Revolution Medicines Inc | 282.9% | Outperformed |
| 3 | Immunitybio inc | 282.9% | Outperformed |
| 4 | Century Therapeutics inc | 282.9% | Outperformed |
| 5 | Inhibrx Biosciences Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Seagen Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Seagen Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Seagen Inc | 43,034.00 | 2,300.35 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Gilead Sciences Inc | 189,197.03 | 30,457.00 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| Argenx Se | 64,196.90 | 8,399.37 |
| SUBTOTAL | 1,110,411.52 | 208,426.53 |
Sign in to see all competitors of Seagen Inc .
Sources: Seagen Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Seagen Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Seagen Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bicycle Therapeutics Plc | Named by the company | 85% |
| Iovance Biotherapeutics inc | Named by the company | 85% |
| BMS | Named by the company | 85% |
| Sutro Biopharma Inc | Named by the company | 85% |
| Corbus Pharmaceuticals Holdings Inc | Named by the company | 85% |
| Puma Biotechnology Inc | Named by the company | 85% |
| Kyowa Kirin | Named by the company | 85% |
| Macrogenics Inc | Named by the company | 85% |
| Bristol-Myers Squibb | Named by the company | 85% |
| Springworks Therapeutics Inc | Named by the company | 85% |
| Cytomx Therapeutics Inc | Named by the company | 85% |
| Acrotech Biopharma | Named by the company | 85% |
| Merck | Named by the company | 85% |
| Mersana Therapeutics inc | Named by the company | 85% |
| Celgene | Named by the company | 85% |
| Urogen Pharma Ltd | Named by the company | 85% |
| Protara Therapeutics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Seagen Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Seagen Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Exelixis Inc | Reportable 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
| Ligand Pharmaceuticals Incorporated | Development and Licensing of Biopharmaceutical Assets 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Seagen Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Seagen Inc | 43,034 | 1,916,959 | -625,187 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Gilead Sciences Inc | 189,197 | 1,791,588 | -190,588 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| Argenx Se | 64,197 | 7,316,521 | 1,125,466 |
| PEERS TOTAL | 1,067,378 | 1,221,293 | 128,978 |
Seagen Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Gilead Sciences Inc | United States 70.78 % |
| Bristol myers Squibb Company | United States 67.79 % |
| United Therapeutics Corporation | UNITED STATES 95.23 % |
| Exelixis Inc | United States 91.44 % |
| Immunitybio inc | United States 98.99 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Seagen Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (93 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 75.40 % | 68.46 % (avg) | +6.9 pp |
| Operating Margin | -34.37 % | industry median | +269.5 pp |
| EBITDA Margin | -28.94 % | -0.94 % (avg) | -28.0 pp |
| Capital Intensity (Capex / Revenue) | 7.00 % | 6.74 % (avg) | +0.3 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Seagen Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (93 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 14.5x | 5.1x | +9.4x |
| Return on Equity | -28.06 % | industry aggregate | -34.18 % |
| Return on Invested Capital | -14.78 % | -6.17 % (avg) | -8.61 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Seagen Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 17.45 % | 24.15 % | 15.33 % | 35.76 % | 40.02 % | 137.32 % | -27.63 % | 24.65 % |
| Operating Margin | -35.91 % | -34.13 % | -40.60 % | -39.71 % | -24.06 % | 27.43 % | -43.32 % | -31.24 % |
| Return on Invested Capital | -12.39 % | -10.28 % | -15.06 % | -9.76 % | -6.91 % | 12.52 % | -10.28 % | -10.53 % |
| P/E | - | - | - | - | - | 55.4x | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Seagen Inc's Strategic Group Map
Every company in Seagen Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Seagen Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Seagen Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 7.00 % vs industry average 6.74 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Seagen Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Seagen Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Seagen Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Seagen Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Seagen Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 269.5 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+12.8% annualized vs trailing 12 months).
Weaknesses
- Return on equity 34.2 points below the industry aggregate.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (55.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-43.7% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Seagen Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Seagen Inc | 0.43 | 3.22 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Gilead Sciences Inc | - | 1.54 | 1.27 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Argenx Se | 2.64 | 5.23 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Seagen Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Seagen Inc | Q3 2023 | +27.1 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Gilead Sciences Inc | Q2 2026 | +10.2 % | - |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| PEERS TOTAL | +12.8 % | -49.3 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Seagen Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Seagen Inc | Q3 2023 | +52.8 % | +175.7 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Gilead Sciences Inc | Q2 2026 | +5.2 % | +30.8 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
Seagen Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Seagen Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Gilead Sciences Inc | - | - | - |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Argenx Se | 14.88% | 14.81% | 17.64% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Seagen Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Seagen Inc | - | 18.71 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Amgen Inc | 25.97 | 5.97 |
| Gilead Sciences Inc | - | 6.21 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| Argenx Se | 49.68 | 7.64 |
| PEERS AVERAGE | 52.83 | 5.33 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.